Smouldering MS as the new frontier
Beyond relapses, smouldering disease is increasingly the lens through which MS therapy is judged.
Multiple sclerosis care has matured around B-cell depletion and high-efficacy therapy. The clinical attention is now on smouldering disease - the slow accumulation of disability between relapses - and what therapies can or cannot do about it.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is spasticity?
- SnapshotAcute ischemic stroke therapy reference (2026)
- ExplainedAcute ischemic stroke explained
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.